Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics

Lipid- and lipoprotein-modifying therapies have expanded substantially in the last 25 years, resulting in reduction in the incidence of major adverse cardiovascular events. However, no specific lipoprotein(a) [Lp(a)]-targeting therapy has yet been shown to reduce cardiovascular disease risk. Many ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Swerdlow, Daniel I, Rider, David A, Yavari, Arash, Wikström Lindholm, Marie, Campion, Giles V, Nissen, Steven E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953457/
https://www.ncbi.nlm.nih.gov/pubmed/33769464
http://dx.doi.org/10.1093/cvr/cvab100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953457/
https://www.ncbi.nlm.nih.gov/pubmed/33769464
http://dx.doi.org/10.1093/cvr/cvab100

Ejemplares similares